A double-blind evaluation of alprazolam and imipramine in the treatment of major depression
- PMID: 21897464
- PMCID: PMC2988295
A double-blind evaluation of alprazolam and imipramine in the treatment of major depression
Abstract
This report describes the results of a multicentre collaborative study comparing the safety and efficacy of alprazolam with imipramine in patients suffering from major depressive disorder. Two hundred and eight patients diagnosed as major depression as per DSM-III criteria were randomly allocated to alprazolam (N= 105) or imipramine (N = 103) in a double-blind fashion. Detailed assessments were carried out for a period of six weeks. Results revealed that alprazolam was as effective as imipramine as an antidepressant. Side effects were less frequently reported with alprazolam.
References
LinkOut - more resources
Full Text Sources
